山東藥玻(600529.SH)控股股東質押1900萬股
格隆匯11月21日丨山東藥玻(600529.SH)公佈,山東魯中投資有限責任公司(以下簡稱“魯中投資”)持有公司股份數量9317.99萬股(無限售流通股),佔公司股份總數的15.66%,為公司控股股東。
公司於2019年11月21日接到控股股東魯中投資函告,獲悉其所持有公司的1900萬股股份被質押,本次質押佔其所持股份的20.39%,佔公司總股本的3.19%。
截至公告披露日,魯中投資累計質押1900萬股股份,佔公司總股本的3.19%,佔其所持公司股份總數的20.39%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.